Drugs / B/F/TAF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02652624 | Feb 2016 → Oct 2017 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-07-21 | Gilead Sciences | Results Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure gilead.com ↗
More than 7,178 person-years of follow-up in PURPOSE 1 and 5,295 person-years in PURPOSE 2 demonstrated continued high efficacy among participants receiving lenacapavir. |
| 2019-07-22 | Gilead Sciences | Results Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance gilead.com ↗
The primary endpoint for this study conducted exclusively in women, was previously presented, and demonstrated noninferior maintained virologic suppression, with a low frequency of serious adverse events and no emergent resistance at Week 48. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-21 | Gilead Sciences | Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure gilead.com ↗ |
| 2019-07-22 | Gilead Sciences | Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance gilead.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B/F/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02652624 ↗ |